CD274 and triple-negative breast carcinoma: It induces nonglycosylated PD-L1 polyubiquitination and destabilization by targeting the β-TrCP E3 ligase, thus reducing the expression of PD-L1 in triple-negative breast cancer cells and enhancing antitumor immunity [211,246].